Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 40.32% is 11% above its 5-year average of 36.34%, near the high end of its 5-year range (8.73%–51.72%).
1.02% below its 12-month average of 40.74%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 33.92%.
GROSS MARGIN
40.32%
GROSS MARGIN AVG TTM
40.74%
GROSS MARGIN AVG 3Y
33.84%
GROSS MARGIN AVG 5Y
36.34%
GROSS MARGIN AVG 10Y
44.19%
GROSS MARGIN AVG 15Y
47.55%
GROSS MARGIN AVG 20Y
49.32%
CURRENT VS TTM AVG
-1.02%
CURRENT VS 3Y AVG
+19.14%
CURRENT VS 5Y AVG
+10.94%
CURRENT VS 10Y AVG
-8.76%
CURRENT VS 15Y AVG
-15.21%
CURRENT VS 20Y AVG
-18.25%
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 724 covered companies
CURRENT VS SECTOR MEDIAN
-0.15%
vs the sector median at left
ImmuCell Corporation
Market Cap
$89.34M
Gross Margin
40.32%
TTM Avg
40.74%
3Y Avg
33.84%
5Y Avg
36.34%
Market Cap
$89.99M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$89.32M
Gross Margin
89.28%
TTM Avg
-3011.26%
3Y Avg
-1505.63%
5Y Avg
-1003.75%
Market Cap
$91.33M
Gross Margin
87.06%
TTM Avg
85.86%
3Y Avg
83.85%
5Y Avg
76.72%
Market Cap
$90.97M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$85.42M
Gross Margin
82.44%
TTM Avg
83.07%
3Y Avg
-40.55%
5Y Avg
-241.44%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ImmuCell Corporation (ICCC) | $89.34M | 40.32% | 40.74% | 33.84% | 36.34% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $89.99M | 0.00% | 0.00% | 0.00% | 0.00% |
| Equillium, Inc. (EQ)vs › | $90.73M | 0.00% | 50.00% | 75.00% | 50.00% |
| Rallybio Corporation (RLYB)vs › | $89.32M | 89.28% | -3011.26% | -1505.63% | -1003.75% |
| electroCore, Inc. (ECOR)vs › | $91.33M | 87.06% | 85.86% | 83.85% | 76.72% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $90.97M | 0.00% | 0.00% | 0.00% | 0.00% |
| CareCloud, Inc. (CCLD)vs › | $86.47M | 46.51% | 45.81% | 42.58% | 41.06% |
| Biomea Fusion, Inc. (BMEA)vs › | $93.01M | 0.00% | 0.00% | 0.00% | 0.00% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.42M | 82.44% | 83.07% | -40.55% | -241.44% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.98M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
40.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 33.92% |
| 2026-03-31 | 44.97% |
| 2025-12-31 | 38.16% |
| 2025-09-30 | 42.92% |
| 2025-06-30 | 43.72% |
| 2025-03-31 | 41.58% |
| 2024-12-31 | 36.53% |
| 2024-09-30 | 26.34% |
| 2024-06-30 | 22.48% |
| 2024-03-31 | 31.63% |
| 2023-12-31 | 24.69% |
| 2023-09-30 | 23.48% |
| 2023-06-30 | 29.55% |
| 2023-03-31 | 8.73% |
| 2022-12-31 | 40.43% |
| 2022-09-30 | 38.49% |
| 2022-06-30 | 44.22% |
| 2022-03-31 | 51.72% |
| 2021-12-31 | 47.04% |
| 2021-09-30 | 46.96% |
| 2021-06-30 | 45.67% |
| 2021-03-31 | 39.01% |
| 2020-12-31 | 43.31% |
| 2020-09-30 | 46.27% |
| 2020-06-30 | 43.27% |
| 2020-03-31 | 45.54% |
| 2019-12-31 | 50.61% |
| 2019-09-30 | 48.86% |
| 2019-06-30 | 46.09% |
| 2019-03-31 | 49.91% |
| 2018-12-31 | 47.53% |
| 2018-09-30 | 44.15% |
| 2018-06-30 | 49.32% |
| 2018-03-31 | 47.19% |
| 2017-12-31 | 38.68% |
| 2017-09-30 | 46.68% |
| 2017-06-30 | 52.66% |
| 2017-03-31 | 60.72% |
| 2016-12-31 | 55.05% |
| 2016-09-30 | 61.21% |
| 2016-06-30 | 52.19% |
| 2016-03-31 | 58.85% |
| 2015-12-31 | 61.52% |
| 2015-09-30 | 65.20% |
| 2015-06-30 | 57.67% |
| 2015-03-31 | 59.68% |
| 2014-12-31 | 60.89% |
| 2014-09-30 | 60.89% |
| 2014-06-30 | 57.06% |
| 2014-03-31 | 55.24% |
| 2013-12-31 | 38.97% |
| 2013-09-30 | 49.87% |
| 2013-06-30 | 57.35% |
| 2013-03-31 | 57.05% |
| 2012-12-31 | 52.80% |
| 2012-09-30 | 57.67% |
| 2012-06-30 | 57.06% |
| 2012-03-31 | 58.97% |
| 2011-12-31 | 55.58% |
| 2011-09-30 | 52.42% |
| 2011-06-30 | 55.68% |
| 2011-03-31 | 55.81% |
| 2010-12-31 | 52.21% |
| 2010-09-30 | 40.89% |
| 2010-06-30 | 57.46% |
| 2010-03-31 | 56.36% |
| 2009-12-31 | 57.17% |
| 2009-09-30 | 59.26% |
| 2009-06-30 | 48.79% |
| 2009-03-31 | 49.39% |
| 2008-12-31 | 45.73% |
| 2008-09-30 | 32.75% |
| 2008-06-30 | 45.93% |
| 2008-03-31 | 50.25% |
| 2007-12-31 | 56.68% |
| 2007-09-30 | 75.33% |
| 2007-06-30 | 46.73% |
| 2007-03-31 | 62.37% |
| 2006-12-31 | 57.37% |
| 2006-09-30 | 60.92% |
| 2006-06-30 | 54.14% |
| 2006-03-31 | 67.04% |
| 2005-12-31 | 66.66% |
| 2005-09-30 | 74.18% |
| 2005-06-30 | 64.53% |
| 2005-03-31 | 64.82% |
| 2004-12-31 | 63.26% |
| 2004-09-30 | 59.43% |
| 2004-06-30 | 54.95% |
| 2004-03-31 | 62.99% |
| 2003-12-31 | 63.26% |
| 2003-09-30 | 57.47% |
| 2003-06-30 | 53.88% |
| 2003-03-31 | 59.02% |
| 2002-12-31 | 69.64% |
| 2002-09-30 | 50.48% |
